Oropharyngeal squamous cell carcinomas (OPSCC) that are associated with human papilloma virus (HPV) infection carry a more favorable prognosis than those that are HPV-negative. However, it remains unclear which biomarker(s) can reliably determine which OPSCC specimens are truly driven by HPV infection. In this study, we analyzed 199 fresh-frozen OPSCC specimens for HPV DNA, viral load, RNA expression patterns typical for cervical carcinomas (CxCaRNA þ ), and the HPV-targeted tumor suppressor protein p16 INK4a as markers for HPV infection.
Introduction
Specific oncogenic types of human papilloma viruses (HPV), most frequently HPV type 16, are causally associated with a subset of oropharyngeal squamous cell carcinomas (OPSCC) (1) (2) (3) (4) . There are some distinct differences between HPV-negative and HPV-positive OPSCC regarding gender, age, tumor histology, size and lymph node involvement, and also in lifestyle and sexual behavior of the patients (2, (5) (6) (7) (8) (9) (10) (11) . Of interest, patients with HPV-positive OPSCC have an improved survival compared with patients with HPV-negative OPSCC (1, 2, 5, 10, (12) (13) (14) .
In several studies, HPV DNA-positive OPSCC were found to be heterogeneous in both biological (e.g., in tumor histology, genetic status of p53, extent of cytogenetic alterations, expression of cell-cycle-related proteins) and clinical behavior (disease progression and patient survival; refs. 1, 3, 9, [15] [16] [17] [18] [19] [20] [21] . Thus, the markers or marker combinations best suited to identify OPSCC with an active HPV involvement (HPV-driven OPSCC) are still unclear.
HPV DNA detection by in situ hybridization (ISH) theoretically should be best suited to identify HPV-driven tumors. However, ISH was found to lack sufficient sensitivity (22) . In contrast, HPV DNA detection by quantitative PCR (qPCR) may lack disease specificity, but it allows precise determination of viral load. Viral load in turn can directly be compared with tumor biology and clinical outcome (8, 9) . Overexpression of p16 INK4a , a consequence of the inactivation of the cellular retinoblastoma protein (pRb) by the viral oncoprotein E7, was proposed to be a surrogate marker for active HPV involvement in OPSCC carcinogenesis (8, 22, 23) . However, high p16
INK4a alone also has insufficient sensitivity (13, (24) (25) (26) and specificity (22, (25) (26) (27) . It was therefore suggested to use HPV DNA positivity in conjunction with high p16
INK4a to detect HPVdriven OPSCC with increased specificity (14, 26, 27) . Because the oncogenic potential of high-risk HPV is mediated through continuous expression of the 2 major viral oncogenes E6 and E7 (28, 29) , E6 and/or E7 RNA expression (in the lack of suitable protein reagents) indeed has shown good value as marker for active HPV (13, 16, 20, 21) .
In HPV16-positive cervical carcinomas (CxCa) and cervical high-grade intraepithelial lesions, 2 characteristic RNA patterns have been found: upregulated E6 Ã II (226^526) and/or E6 Ã I (226^409) transcripts with a concurrently low or absent expression of the E1^E4 (880^3358) transcript (high E6 Ã / E1^E4) and/or upregulated E1C (880^2582) transcript with a concurrently low or absent L1 (3632^5639) transcript (high E1C/L1; ref. 30) . Whether HPV-positive OPSCC express viral RNA patterns as in CxCa is unclear. Also, viral load and expression of viral RNA patterns have not been directly compared with regard to clinical behavior and patient survival.
In this large German OPSCC case series (n ¼ 199), the HPV DNA-positive tumors were analyzed in detail for viral load, viral oncogene RNA (E6 Ã II and/or E6 Ã I), and CxCa-like viral RNA patterns (CxCaRNA). We hypothesized that CxCa-like viral RNA patterns should be the best marker to identify truly HPV-driven OPSCC and, therefore, these patterns should be associated with the most favorable patient survival. It was further of interest to examine whether high p16
INK4a expression is concordant with these CxCa-like viral RNA patterns.
Materials and Methods

Patients, tissue samples
Of the patients diagnosed with primary OPSCC and treated at the ENT Department of the University Hospital Heidelberg, Germany, between 1990 and 2008, 199 gave informed consent and provided fresh-frozen tumor biopsies. The study was approved by the Ethics Committee of the Medical Faculty of the University of Heidelberg, study code 176/2002. Biopsies were directly snap-frozen in precooled isopentane/liquid nitrogen and stored at À80 C until further processing. Patient and tumor characteristics were obtained from clinical records. Management decisions for the patients were not guided by knowledge of HPV status or p16
INK4a expression. Information on first-line treatment modality was available for 184 patients. In 125 patients, surgery was applied, and in 59 patients with poor performance status or with nonresectable tumors, radiation and/or chemotherapy were applied first.
For nucleic acid extractions, cryosections of 16-mm thickness yielding between 2 and 10 mg of tissue were cut, homogenized in liquid nitrogen, and stored at À80 C. After each biopsy, the cryostat was cleaned with acetone and ethanol and new gloves, forceps, and blades were used. For each homogenization, a fresh pistil was used. As negative controls, 2 mucosal biopsies from healthy patients were processed in the same way. To verify the presence and to estimate the content of tumor cells in cryosections, adjacent sections were stained with hematoxylin and eosin. The mean tumor cell content was 55% (range, 25%-90%).
Multiplex HPV genotyping and real-time qPCR for viral load determination DNA was isolated using Qiagen's QIAamp DNA Mini Kit. Twenty-seven mucosal HPV types were analyzed simultaneously by BSGP5þ/6þ-PCR/MPG as described (31) (32) (33) . The BSGP5þ/6þ-PCR/MPG assay comprises the BSGP5þ/6þ-PCR, which homogenously amplifies all known genital HPV types generating biotinylated amplimers of approximately 150 bp from the L1 region (32, 33) and a multiplex HPV genotyping (MPG) assay with bead-based xMAP Luminex suspension array technology, which is able to simultaneously identify 27 HPV types and the b-globin gene (31, 32) . The assay coamplifies cellular b-globin sequences as internal DNA quality control.
Quantification of HPV16 signals was accomplished as follows: to yield a relative HPV16 signal (in%), each measured HPV16 signal was first divided by the highest HPV16 signal observed among all tumor samples; the resulting relative HPV16 signal was then divided by the b-globin signal of the same sample to give a normalized viral load value (%HPV signal/b-globin signal). A cutoff between low and high viral load of 0.0007 units was chosen. This high viral load cutoff has been developed for high-risk HPV types and optimized to distinguish cervical smears with normal cytology from those with abnormal cytology (manuscript in preparation).
Tumors positive for HPV16 DNA by BSGP5þ/6þ-PCR/MPG (HPV þ ) were further analyzed using real-time qPCR targeting HPV16-specific sequences of the E6 gene to obtain quantitative viral load values and an objective high viral load cutoff. qPCR for b-globin was used to verify the quality of DNA in the sample and to measure the amount of input DNA. Viral load in each specimen was expressed as the number of HPV genome copies per cell. Because on average the specimens contained approximately 50% tumor cells and at least 1 genome copy per cell is expected in HPV-transformed cells, we defined 0.5 copies per cell as cutoff for a high viral load (HPV high ) and OPSCC below this cutoff had a low viral load (HPV low ). Primer sequences used for real-time qPCR are available upon request (manuscript in preparation).
HPV16 RNA analysis HPV16 DNA-positive OPSCC determined by BSGP5þ/6þ-PCR/MPG were analyzed for viral RNA expression. RNA was isolated using Qiagen's RNeasy Mini Kit. DNase I digestion (Qiagen) was included to ensure an exclusive amplification of RNA. Nucleic acid sequence-based amplification and hybridization to splice-specific probes on Luminex beads were carried out as described (30 
Statistical analysis
Patient and tumor characteristics were analyzed in relation to their HPV16 DNA and RNA status. Overall survival (OS) was measured as the time from the date of primary tumor diagnosis to the date of OPSCC-related death. One-hundred and eleven patients died during this study, out of which only 9 patients died unrelated to OPSCC. Survival times of patients who were alive at the date of last follow-up or were dead because of causes other than OPSCC were censored. Progression-free survival (PFS) time was calculated from the date of primary tumor diagnosis to the date of the first local recurrence, lymph node or distant metastasis, second primary carcinoma or date of OPSCC-related death (events), or to the date of OPSCCunrelated death or last follow-up without progression (censored). Follow-up data after diagnosis were obtained from electronic health records of the University Hospital. In case of incomplete records, the resident physicians were contacted to obtain the follow-up data. The cutoff date for follow-up was 31 December, 2009. Thirty-five of 199 (18%) patients were not completely followed. However, the baseline characteristics, for example, age, gender, clinical stage, therapy status, and the distribution of HPV status of these patients were similar to the patients with complete follow-up. The method of Kaplan and Meier was used to estimate survival distributions. Median duration of follow-up was calculated according to Korn (37 INK4a expression represented the reference category. Cox models were built using missing value imputation for all covariates by application of bootstrap resampling (38) . The proportional hazards assumption, required for valid inference in Cox proportional hazards regression, was tested according to Grambsch and Therneau (39) and was met for all covariates. The ability of the prediction models to classify risk for death and disease progression was assessed by computing the area under the time-dependent receiver operating characteristic (ROC) curves (40) . To summarize and compare the prediction accuracy of the different Cox models, we calculated the integrated Brier score as a summary of the prediction error curve over the time interval of 5 years from date of primary tumor diagnosis (41) . The prediction error was computed by the 0.632þ bootstrap estimate (42) .
In all statistical tests a P value of 0.05 or below was considered as statistically significant. The statistical analyses were carried out using SAS, version 9.2, as well as the statistical software environment R, version 2.12.2.
Results
HPV-type prevalence and viral load
All 199 OPSCC biopsies yielded DNA of good quality with the b-globin gene coamplified in each sample. Of 100 OPSCC (50%) positive for HPV DNA analyzed by BSGP5þ/6þ-PCR/MPG, 97 contained HPV16 DNA (HPV þ , Table 1 , Fig. 1 Fig. 1 ). Of these, 12 (25%) displayed high E6 Ã /E1^E4, 25 (52%) displayed high E1C/L1, and 3 (6%) displayed both patterns (Fig. 2) Table 2 ).
OS and PFS in relation to HPV DNA, RNA, and p16
INK4a
The median follow-up time for this study was 103 months. In the HPV þ group, both OS and PFS were better than in the HPV À group (median survival times 61 and 32 months in HPV þ patients vs. 26 and 12 months in HPV À patients, respectively; Fig. 4A and B). However, stratifying the patients by viral load or RNA status revealed larger differences, and the strongest differences between survival curves was seen in the CxCaRNA þ or the HPV transf þ group (Fig. 4C-F provide improved OS or PFS over p16-high alone (Fig. 4I  and J) .
Multivariate Cox regression using only demographic, clinical, and behavioral factors showed a statistically significant association of clinical stage IV (OS only), current tobacco consumption (PFS only), and the first-line therapy with a shorter survival (Table 3) . Most notable, Cox proportional hazard models of HPV markers adjusting for demographic, Table S1 ). Similar results were obtained with respect to the area under the time-dependent ROC curves (Supplementary Fig. S2 ).
Discussion
We analyzed 199 OPSCC for the active involvement of HPV16 using viral load, viral oncogene RNA, CxCa-like viral RNA patterns, and p16
INK4a as markers. For the first time, we assessed whether the HPV16 DNA-positive OPSCC displayed similar viral RNA patterns as seen in HPV16-positive CxCa. By HPV DNA status only, HPV þ and HPV À tumors were marginally distinct entities, since they showed similar survival curves, and in multivariate Cox proportional hazard models, patients with HPV þ tumors had no statistically significantly better outcome in OS and PFS compared with patients with HPV À tumors ( Table 3) . We are aware that some of the HPV low tumors in our cohort likely in respect to HPV-driven OPSCC were false positive because of the presence of low amounts of HPV DNA in the tissues resulting from past infection that had not progressed to malignancy or from recent oral exposure to the virus. However, the use of high sensitivity detection technology with high viral load quantitation was justified since we clearly detected HPV low tumors in which HPV16 was transcriptionally active (see below Supplementary Fig. S1 ). We believe that the large number of discordant cases in our study population was not because of some technical problems, but reflects true differences in the biology of HPV16-associated OPSCC and HPV16-positive CxCa, because in a parallel study on CxCa, only 1 of 58 cervical tumors lacked p16
INK4a overexpression (43) . Thus, our results are in conflict with some reports in the literature in which only very few HPV-positive OPSCC or HNSCC were not showing high p16
INK4a expression and hence p16
INK4a was proposed to provide a cellular surrogate marker for HPV involvement and predictor of improved survival (8, 22, 23, 44) . Our results are in agreement with other studies in which the combination of high p16
INK4a with positive HPV DNA typing was proposed to better correlate with active HPV involvement and improved patient survival than high p16 INK4a alone (14, 26, 27) . However, the combination p16-high and HPV þ did not match high viral load or viral RNA pattern analysis (p16-high and HPV þ vs. HPV À , HR ¼ 0.55; 95% CI, 0.29-1.08; Table 3) . Surprisingly, both p16-high and the combination p16-high and HPV þ had some beneficial effect on OS but not on PFS (Table 3 ). The reason for this is unclear. However, our data did not reveal any differential impact of p16
INK4a overexpression in HPV DNA-positive versus HPV DNA-negative OPSCC as was observed by Smith and colleagues (26) . A limitation of this study is that we could not confirm improved prediction accuracy of the CxCa-like RNA patterns over RNA þ by statistical analysis, probably because of the small number of RNA þ tumors without CxCa-like RNA patterns (n ¼ 8). However, because the HR for the 8 CxCaRNA À tumors was similar to the HR of the tumors without transcriptionally active HPV16 (RNA À and HPV À group), and since they also showed similar histology, tumor subsite distribution, and patient outcome (data not shown), we conclude that CxCaRNA À tumors behave like HPV À tumors. It may be helpful for future studies to develop a quantitative cutoff for viral RNA copy numbers per OPSCC tumor cell. The prevalence in OPSCC of both HPV16 DNA (49%) and, in particular, the CxCa-like RNA patterns (20%; the latter reflecting biological activity of HPV16) in this study are in line with several previous Western European studies (16, 17, 20, 21, 23, 44) , but are distinctly lower than reported in the major Scandinavian and North American studies (5, 7, 13, 15, 45) . In these, the reported HPV prevalence ranged from 65% to 80% and absent HPV RNA expression was exceptional, indicating that nearly all of these tumors harbored active virus. The reasons for these relative prevalence differences in active HPV16 involvement between the North American/Scandinavian and Western European study populations are unclear, at present.
In conclusion, by using highly sensitive HPV DNA and RNA detection technologies, we not only detected OPSCC with high viral load and with CxCa-like viral RNA patterns but also a fraction of tumors with low viral load in which the transcriptional activity of the virus indicated a carcinogenic role. These tumors represent a clinically distinct subgroup with significantly better OS and PFS. The viral markers were superior over p16
INK4a expression as diagnostic and prognostic biomarkers. Patients with HPV-driven OPSCC have been shown to have better survival even with radiochemotherapy as primary treatment modality. In situations like in Germany, with heterogeneity among the HPV DNA-positive tumor patients, precise definition of HPV activity in the tumor as suggested here could help in selection of the primary treatment modality.
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